LCN2 and acute kidney injury: This prospective, double-blind, randomized, and placebo-controlled trial has shown that prophylaxis with rHuEPO reduced the incidence of CSA-AKI, decreased the length of ICU and hospital stays and attenuated renal injury as assessed by the sensitive biomarker urine NGAL.